Thumbnail Image
Publication

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James, N
; 
Sydes, M
; 
Clarke, Noel W
; 
Mason, M
; 
Dearnaley, D
; 
Spears, M
; 
Ritchie, A
; 
Parker, C
; 
Russell, J
; 
Attard, G
... show 10 more
Citations
Altmetric:
Abstract
Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.
Authors
James, N
Sydes, M
Clarke, Noel W
Mason, M
Dearnaley, D
Spears, M
Ritchie, A
Parker, C
Russell, J
Attard, G
de Bono, J
Cross, W
Jones, R
Thalmann, G
Amos, CL
Matheson, D
Millman, R
Alzouebi, M
Beesley, S
Birtle, A
Brock, S
Cathomas, R
Chakraborti, P
Chowdhury, S
Cook, A
Elliott, T
Gale, J
Gibbs, S
Graham, J
Hetherington, J
Hughes, R
Laing, R
McKinna, F
McLaren, D
O'Sullivan, J
Parikh, O
Peedell, C
Protheroe, A
Robinson, A
Srihari, N
Srinivasan, R
Staffurth, J
Sundar, S
Tolan, S
Tsang, D
Wagstaff, J
Parmar, M
Affiliation
Warwick Medical School, University of Warwick, Coventry, UK
Description
Date
2015-12-21
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL
Adobe PDF, 693.94 KB
Keywords
Type
Article
Citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2015: Lancet
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/594615
Embedded videos